Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia - Related Studies

Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

This study is currently recruiting participants.

Study NCT00625729. Last updated on October 25, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Leukemia
		Lymphoma

2	Additional conditions recognized in this trial
		Leukemia, B-Cell
		Leukemia, Lymphocytic, Chronic, B-Cell
		Leukemia, Lymphoid
		Lymphoma, Non-Hodgkin

3	More general conditions related to this trial
		Immune System Diseases
		Immunoproliferative Disorders
		Lymphatic Diseases
		Lymphoproliferative Disorders
		Neoplasms
		Neoplasms by Histologic Type

4	Interventions listed in this trial
		aldesleukin
		cyclophosphamide
		fludarabine phosphate
		lymphokine-activated killer cells
		rituximab
		biomarker analysis
		pharmacogenomic studies
		pharmacological study

5	Additional drug interventions recognized in this trial
		Fludarabine
		Fludarabine monophosphate

6	More general drug interventions related to this trial
		Alkylating Agents
		Anti-HIV Agents
		Anti-Infective Agents
		Anti-Retroviral Agents
		Antimetabolites
		Antimetabolites, Antineoplastic
		Antineoplastic Agents
		Antineoplastic Agents, Alkylating
		Antirheumatic Agents
		Antiviral Agents
		Immunologic Factors
		Immunosuppressive Agents
		Molecular Mechanisms of Pharmacological Action
		Myeloablative Agonists
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses

7	Sponsors listed in this trial
		Masonic Cancer Center, University of Minnesota
		National Cancer Institute (NCI)